Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that the European Commission (EC), acting upon the positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products, has granted Orphan drug designation to SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne).
“This Orphan designation recognizes SGT-003’s potential to address the significant unmet need in Duchenne muscular dystrophy and supports our firm commitment to advancing SGT-003 for patients globally,” said Jessie Hanrahan, Ph.D., Chief Regulatory & Preclinical Operations Officer at Solid Biosciences.
Read more about Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy.
